Timothy Dec Biography and Net Worth

CFO of Supernus Pharmaceuticals

Timothy C. Dec has served as our Senior Vice-President of Finance since August 2021. Mr. Dec has more than 35 years of experience in accounting and finance across many industries, including healthcare. His experience includes serving in chief financial officer or other senior financial executive roles at three publicly traded companies listed on Nasdaq, and with private equity-backed companies. Most recently, from April 2015 to July 2021, Mr. Dec was Chief Financial Officer of OpGen, Inc., a Nasdaq listed company engaged in the development and commercialization of molecular microbiology solutions to help combat infectious diseases. Prior to joining OpGen, Mr. Dec served as Senior Vice President and Chief Financial Officer for Clubwidesports, LLC, a start-up sports management software company, from January 2014 to April 2015. From August 2007 to December 2012, Mr. Dec served as Senior Vice President and Chief Financial Officer of Fortress International Group, Inc., a publicly traded company. From June 2006 to August 2007, Mr. Dec was Senior Vice President, Chief Financial Officer of Presidio Networked Solutions, a private company, and from June 1999 to June 2006, was Senior Vice President, Chief Accounting Officer and Treasurer of Broadwing Corporation (formerly Corvis Corporation), a publicly traded company. Mr. Dec also has public accounting firm experience and served as an Adjunct Professor teaching M.B.A courses in finance at Mount St. Mary’s University from January 2013 to August 2017. Mr. Dec received his B.S. in accounting from Mount St. Mary’s University and an M.B.A. in finance from American University.

What is Timothy C. Dec's net worth?: The estimated net worth of Timothy C. Dec is at least $56.19 thousand as of August 22nd, 2025. Dec owns 1,246 shares of Supernus Pharmaceuticals stock worth more than $56,195 as of December 4th. This net worth estimate does not reflect any other assets that Dec may own. Additionally, Dec receives an annual salary of $635,430.00 as CFO at Supernus Pharmaceuticals. Learn More about Timothy C. Dec's net worth.
How old is Timothy C. Dec?: Dec is currently 65 years old. There are 6 older executives and no younger executives at Supernus Pharmaceuticals. The oldest executive at Supernus Pharmaceuticals is Ms. Tami T. Martin Esq., R.N., Senior Vice President of Regulatory Affairs, who is 69 years old. Learn More on Timothy C. Dec's age.
What is Timothy C. Dec's salary?: As the CFO of Supernus Pharmaceuticals, Inc., Dec earns $635,430.00 per year. The highest earning executive at Supernus Pharmaceuticals is Mr. Jack A. Khattar, Founder, President, CEO, Secretary & Director, who commands a salary of $1,630,000.00 per year. Learn More on Timothy C. Dec's salary.
How do I contact Timothy C. Dec?: The corporate mailing address for Dec and other Supernus Pharmaceuticals executives is 1550 E GUDE DR, ROCKVILLE MD, 20850. Supernus Pharmaceuticals can also be reached via phone at (301) 838-2500 and via email at [email protected]. Learn More on Timothy C. Dec's contact information.
Has Timothy C. Dec been buying or selling shares of Supernus Pharmaceuticals?: Timothy C. Dec has not been actively trading shares of Supernus Pharmaceuticals in the last ninety days. Most recently, Timothy C. Dec sold 11,780 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $44.49, for a transaction totalling $524,092.20. Following the completion of the sale, the chief financial officer now directly owns 1,246 shares of the company's stock, valued at $55,434.54. Learn More on Timothy C. Dec's trading history.
Who are Supernus Pharmaceuticals' active insiders?: Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Timothy Dec (CFO), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development), and Bethany Sensenig (Director). Learn More on Supernus Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Supernus Pharmaceuticals?: In the last twelve months, insiders at the specialty pharmaceutical company sold shares 16 times. They sold a total of 373,845 shares worth more than $16,830,854.81. The most recent insider tranaction occured on October, 9th when CEO Jack A Khattar sold 59,900 shares worth more than $3,029,143.00. Insiders at Supernus Pharmaceuticals own 8.8% of the company. Learn More about insider trades at Supernus Pharmaceuticals.
Information on this page was last updated on 10/9/2025.

Timothy C. Dec Insider Trading History at Supernus Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/22/2025	Sell	11,780	$44.49	$524,092.20	1,246

Timothy C. Dec Buying and Selling Activity at Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Overview

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Today's Range

Now: $45.10

$44.28

$45.10

50 Day Range

MA: $48.40

$44.12

$57.00

2 Week Range

Now: $45.10

$29.16

$57.65

Volume

493,657 shs

Average Volume

807,434 shs

Market Capitalization

$2.59 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Timothy Dec Biography and Net Worth

What is Timothy C. Dec's net worth?

How old is Timothy C. Dec?

What is Timothy C. Dec's salary?

How do I contact Timothy C. Dec?

Has Timothy C. Dec been buying or selling shares of Supernus Pharmaceuticals?

Who are Supernus Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Supernus Pharmaceuticals?